Business Description
Quest Diagnostics Inc
NAICS : 621511
SIC : 8071
ISIN : US74834L1008
Share Class Description:
DGX: Ordinary SharesTotal Employee Number:
57,000Compare
Compare
Traded in other countries / regions
DGX.USA0KSX.UKQDI.Germany1QDX.ItalyDGX.MexicoQ1UE34.Brazil Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1996-12-17Description
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.87 | |||||
Debt-to-EBITDA | 2.88 | |||||
Interest Coverage | 5.98 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 3.44 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.3 | |||||
3-Year EBITDA Growth Rate | 7.5 | |||||
3-Year EPS without NRI Growth Rate | -0.3 | |||||
3-Year FCF Growth Rate | 2.6 | |||||
3-Year Book Growth Rate | 7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.27 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.63 | |||||
9-Day RSI | 58.36 | |||||
14-Day RSI | 58.06 | |||||
3-1 Month Momentum % | 1.4 | |||||
6-1 Month Momentum % | 4.36 | |||||
12-1 Month Momentum % | 17.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.18 | |||||
Quick Ratio | 1.08 | |||||
Cash Ratio | 0.18 | |||||
Days Inventory | 9.46 | |||||
Days Sales Outstanding | 47.08 | |||||
Days Payable | 14.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.57 | |||||
Dividend Payout Ratio | 0.34 | |||||
3-Year Dividend Growth Rate | 25.9 | |||||
Forward Dividend Yield % | 1.62 | |||||
5-Year Yield-on-Cost % | 2.67 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 1.57 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 33.2 | |||||
Operating Margin % | 14.31 | |||||
Net Margin % | 9.08 | |||||
EBITDA Margin % | 19.71 | |||||
FCF Margin % | 11.76 | |||||
OCF Margin % | 16.4 | |||||
ROE % | 14.24 | |||||
ROA % | 6.33 | |||||
ROIC % | 8.44 | |||||
3-Year ROIIC % | 1.79 | |||||
ROC (Joel Greenblatt) % | 48.51 | |||||
ROCE % | 11.62 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.28 | |||||
Forward PE Ratio | 19.58 | |||||
PE Ratio without NRI | 21.72 | |||||
Shiller PE Ratio | 21.92 | |||||
Price-to-Owner-Earnings | 18.38 | |||||
PS Ratio | 2.11 | |||||
PB Ratio | 3.17 | |||||
Price-to-Free-Cash-Flow | 17.91 | |||||
Price-to-Operating-Cash-Flow | 12.85 | |||||
EV-to-EBIT | 18.05 | |||||
EV-to-Forward-EBIT | 17.83 | |||||
EV-to-EBITDA | 13.37 | |||||
EV-to-Forward-EBITDA | 13.2 | |||||
EV-to-Revenue | 2.63 | |||||
EV-to-Forward-Revenue | 2.47 | |||||
EV-to-FCF | 22.41 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Projected-FCF | 1.26 | |||||
Price-to-Median-PS-Value | 1.14 | |||||
Earnings Yield (Greenblatt) % | 5.54 | |||||
FCF Yield % | 5.69 | |||||
Forward Rate of Return (Yacktman) % | -0.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:DGX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quest Diagnostics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 11,278 | ||
| EPS (TTM) ($) | 9.05 | ||
| Beta | 0.184 | ||
| 3-Year Sharpe Ratio | 0.56 | ||
| 3-Year Sortino Ratio | 0.91 | ||
| Volatility % | 26.7 | ||
| 14-Day RSI | 58.06 | ||
| 14-Day ATR ($) | 4.976971 | ||
| 20-Day SMA ($) | 207.303 | ||
| 12-1 Month Momentum % | 17.59 | ||
| 52-Week Range ($) | 165.3 - 219.2 | ||
| Shares Outstanding (Mil) | 110.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quest Diagnostics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quest Diagnostics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-21 08:30 | In 96 days | ||
| Third quarter earnings results for 2026 | 2026-10-21 | In 95 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 08:30 | In 6 days | ||
| Second quarter earnings results for 2026 | 2026-07-23 | In 5 days | ||
| USD 0.860000 Cash Dividend | 2026-07-08 | 212.38 (-2.08%) | ||
| General meeting for 2026 | 2026-05-20 10:30 | 190.39 (+0.61%) | ||
| First quarter earnings conference call for 2026 | 2026-04-21 08:30 | 196.31 (+1.08%) | ||
| First quarter earnings results for 2026 | 2026-04-21 | 196.31 (+1.08%) | ||
| USD 0.860000 Cash Dividend | 2026-04-06 | 198.02 (+0.69%) | ||
| Guidance call for 2026 | 2026-03-11 08:00 | 200.90 (-1.11%) |
Show
Entries
Quest Diagnostics Inc Frequently Asked Questions
What is Quest Diagnostics Inc(DGX)'s stock price today?
The current price of DGX is $210.68. The 52 week high of DGX is $219.20 and 52 week low is $165.30.
When is next earnings date of Quest Diagnostics Inc(DGX)?
The next earnings date of Quest Diagnostics Inc(DGX) is 2026-07-23.
Does Quest Diagnostics Inc(DGX) pay dividends? If so, how much?
The Dividend Yield %  of Quest Diagnostics Inc(DGX) is 1.57% (As of Today), Highest Dividend Payout Ratio of Quest Diagnostics Inc(DGX) was 0.4. The lowest was 0.17. And the median was 0.32. The  Forward Dividend Yield % of Quest Diagnostics Inc(DGX) is 1.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Quest Diagnostics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers